Contineum Therapeutics PIPE-791 Shows Positive Phase 1b Results for Chronic Osteoarthritis Pain

Key Takeaways

• PIPE-791 demonstrated positive topline results in Phase 1b trial for chronic osteoarthritis pain
• The drug targets LPA1 receptors as a non-opioid alternative for pain management
• Results support advancement to later-stage clinical development for this potential best-in-class therapy

---

Contineum Therapeutics, Inc. (NASDAQ: CTNM) announced positive topline data from its exploratory Phase 1b clinical trial of PIPE-791, a selective lysophosphatidic acid 1 (LPA1) receptor antagonist being developed as a non-opioid treatment for chronic osteoarthritis pain.

The San Diego-based clinical-stage biopharmaceutical company is focusing on differentiated therapies for neuroscience, inflammation, and immunology conditions. PIPE-791 represents a potentially best-in-class approach to pain management by targeting the LPA1 receptor pathway.

Clinical Trial Significance

The Phase 1b trial results mark an important milestone for Contineum’s pain management pipeline. LPA1 receptor antagonists represent a novel mechanism of action that could provide effective pain relief without the addiction risks associated with opioid medications.

Chronic osteoarthritis affects millions of patients worldwide, creating substantial demand for safe and effective non-opioid pain treatments. Current treatment options often provide limited efficacy or carry significant side effects, highlighting the medical need for innovative approaches like PIPE-791.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Next Steps

The positive Phase 1b data positions Contineum to advance PIPE-791 into later-stage clinical development. The company’s focus on neuroscience, inflammation, and immunology indications aligns with growing pharmaceutical industry investment in these therapeutic areas.

For investors and stakeholders, these results demonstrate progress in Contineum’s clinical pipeline and validate the company’s approach to targeting underserved patient populations with novel mechanisms of action.

The biopharmaceutical industry continues seeking alternatives to opioid-based pain management, making PIPE-791’s non-opioid profile particularly valuable in the current regulatory and clinical environment focused on addressing the opioid crisis while maintaining effective pain treatment options.

---

Frequently Asked Questions

What does this mean for patients with chronic osteoarthritis?

The positive Phase 1b results suggest PIPE-791 could provide a new non-opioid treatment option for chronic osteoarthritis pain, though the drug still requires additional clinical testing before potential approval.

When will PIPE-791 be available to patients?

PIPE-791 is still in early clinical development. The drug will need to complete Phase 2 and Phase 3 trials successfully before seeking regulatory approval, which typically takes several years.

How does PIPE-791 compare to existing pain treatments?

PIPE-791 targets the LPA1 receptor pathway, offering a different mechanism than current pain medications. Its non-opioid profile could provide pain relief without addiction risks associated with opioid treatments.

Related coverage

• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
• J&J reports positive Phase 3 Tremfya data in ulcerative colitis